Non-HDL cholesterol is a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population

Abstract

OBJECTIVES:

Increased arterial stiffness is an important determinant of the risk of cardiovascular disease. Lipid profile impairment, especially hypercholesterolemia, is associated with stiffer blood vessels. Thus, the aim of this study was to determine which of the five circulating lipid components (high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), low-density lipoprotein cholesterol (LDL), total cholesterol (TC) and triglycerides) is the best predictor of increased arterial stiffness in an urban Brazilian population.

METHODS:

A random sample of 1,662 individuals from the general population of Vitoria, Brazil (25-64 years), was selected, and lipid components were measured using standard methods. Pulse wave velocity was measured using a non-invasive automatic device, and increased arterial stiffness was defined as a pulse wave velocity ≥10 m/s.

RESULTS:

In men, only total cholesterol (OR=1.59; CI=1.02 to 2.48, p=0.04) was associated with the risk of increased arterial stiffness. In women, HDL-C (OR=1.99; CI=1.18 to 3.35, p=0.01) and non-HDL-C (OR=1.61; CI=1.01 to 2.56, p=0.04) were good predictors of the risk of increased arterial stiffness. However, these associations were only found in postmenopausal women (OR=2.06; CI=1.00 to 4.26, p=0.05 for HDL-C and OR=1.83; CI=1.01 to 3.33, p=0.04 for non-HDL-C).

CONCLUSION:

Our findings indicate that both HDL-C and non-HDL-C are good predictors of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population and may be useful tools for assessing the risk of arterial stiffness.

Non-HDL-C; Arterial Stiffness; Dyslipidemia; Menopause

INTRODUCTION

Increased arterial stiffness is an important determinant of cardiovascular disease (CVD) risk (¹). Several epidemiological studies have reported that increased arterial stiffness predicts morbidity and mortality independently of other cardiovascular risk factors (²,³). Stiffness of the large arteries, which is measured using carotid-femoral pulse wave velocity (PWV) - the gold standard method for assessing this parameter - has been associated with measures of subclinical atherosclerosis and CVD (⁴). Furthermore, clinical studies have shown that arterial stiffness increases with age or in several pathological processes, such as hypertension, metabolic syndrome, chronic renal disease, hypercholesterolemia, and menopause (⁵-¹⁰).

Changes in the lipid profile, especially hypercholesterolemia, may contribute to changes in vascular stiffness (⁹). Several studies have recently investigated the association between arterial stiffness and lipid profile-related parameters, such as non-high-density lipoprotein cholesterol (non-HDL-C), low density lipoprotein cholesterol (LDL-C) and the non-HDL/HDL-C ratio (¹¹-¹³). However, the results reported to date are far from conclusive because the results of only 10% of the studies on this subject suggested that a positive association exists between these variables, while most of the studies failed to find such a correlation between the variables (¹⁴). In addition, the results of the studies showing that any serum lipid parameter is a superior predictor of the risk of increased arterial stiffness compared to other lipid profile parameters are still inconclusive.

Based on this scenario and on the clinical applicability of lipid profile and arterial stiffness measurements, the aim of this study was to determine which of the five measurements recommended to assess cardiovascular risk (HDL-C, non-HDL-C, LDL-C, total cholesterol (TC) and triglycerides) is the best predictor of the risk of increased arterial stiffness in an urban Brazilian population. Moreover, we also assessed the possible influence of menopause on PWV values.

METHODS

Subjects

A study of the risk factors for CVDs was performed in the urban population of Vitoria, Brazil, using the WHO-MONICA Project guidelines (¹⁵). The study design was based on a cross-sectional research methodology and was developed by surveying and analyzing socioeconomic and health data in a probabilistic sample of residents from the municipality of Vitoria, Espírito Santo, Brazil. The objective of the sampling plan was to ensure that the research was socioeconomically, geographically, and demographically representative of the residents of this municipality. Residents of the city of Vitoria ranging from 25-64 years of age were included in the study. According to the census conducted by the IBGE Foundation in 1996, the resident population of Vitoria included 265,874 inhabitants. Sampling was performed in four stages as follows: by district, by IBGE census sector, by drawing lots to choose homes, and by birthday to choose an individual from each home. The survey was conducted with only one resident (chosen according to the nearest birthday after homes were randomly selected) from the selected home who was within the aforementioned age range of the study. The draw was conducted using a randomization mechanism. A total of 2,268 residential homes were selected and visited. The research purposes were explained to the individual selected in his/her home, and he/she was invited to participate in the study after providing his/her written consent. The selected individuals were asked to visit the Cardiovascular Investigation Clinic of the University Hospital within 2 weeks after selection so that their tests could be performed. Among the total sample, 1,662 individuals (761 men and 901women) visited the clinic. This study was approved by the Ethics Committee for Research on Human Subjects of the Espírito Santo Federal University and the National Ethics Committee for Human Research (CONEP Register Number 4599).

Anthropometrical Investigations

Anthropometric parameters were measured according to a standard protocol (¹⁶). Body weight was measured to the nearest 0.1 kg on a calibrated scale, and height was measured to the nearest 0.5 cm using a wall-mounted stadiometer. Waist circumference was measured at the mean point between the lowest rib margin and the iliac crest at the maximum point of normal expiration while the subject stood (¹⁷). Body mass index (BMI) was calculated as body weight (kg) divided by height squared (m²).

Biochemical Measurements

Blood glucose levels, triglyceride levels and lipoprotein fractions were assayed with standard techniques using 12-h fasting blood samples (¹⁸). Non-HDL-C was calculated by subtracting HDL-C from TC. The following biochemical parameter results were categorized as abnormal: a TC level ≥240 mg/dL, a triglyceride level ≥200 mg/dL, an LDL-C level ≥160 mg/dL, an HDL-C level ≤39 mg/dL, and a non-HDL-C level ≥190 mg/dL (¹⁹). Diabetes mellitus was diagnosed based on the presence of a fasting glucose level ≥126 mg/dL and/or antidiabetic drug use (²⁰), and hyperlipidemia was defined as a TC level ≥240 mg/dL, an LDL-C level ≥160 mg/dL, and/or hypolipidemic drug use (²¹).

PWV Determination

Carotid-femoral PWV was measured with the patient in the supine position with an automatic and validated device (Complior; Artech Medical, France) operated by an experienced observer who was blinded to the patients’ clinical characteristics. Briefly, common carotid artery and femoral artery pressure waveforms were recorded non-invasively using pulse-sensitive transducers. PWV was measured within a period ranging from 10-15 seconds, and carotid-femoral distance was used to assess PWV. The distance between the recording sites (D) was measured, and PWV was calculated automatically as PWV=D/t, where (t) is the pulse transit time. The measurements were repeated over 10 different cardiac cycles. According to recent recommendations, increased arterial stiffness was defined as a PWV≥10 m/s (²²). The validation of this automatic method and its reproducibility have been described previously (²³).

Assessment of Menopausal Status

Information regarding the menopausal statuses of the women in the present study was evaluated using a questionnaire that was completed by each participant in an interview during the clinic visit. The questionnaire was based on the WHO-MONICA epidemiological instrument (¹⁵) and was administered and filled out by research assistants who were specially trained for the task.

Statistical Analysis

Categorical variables are presented as percentages, whereas continuous variables are presented as the mean±standard deviation. Binary logistic regression analysis was performed to evaluate the associations between lipid profile parameters (HDL-C, non-HDL-C, LDL-C, TC and triglycerides) and arterial stiffness, allowing for covariates (mean blood pressure and age). The data are presented as odds ratios (ORs) and 95% confidence intervals (CIs). The same analysis was also performed second time only for women and was stratified by menopausal status (premenopausal and postmenopausal women). Statistical analyses were conducted using IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY, USA, with the level of significance set at 5%.

RESULTS

The results are presented such that they emphasize the relationship between lipid components and increased arterial stiffness in women because some lipid components were strongly associated with increased arterial stiffness in this group, especially in postmenopausal women.

Stratified by sex, the demographic data related to age, BMI, waist circumference, fasting glucose, PWV, TC, HDL-C, LDL-C, non-HDL-C, very-low-density lipoprotein cholesterol (VLDL), triglycerides and the presences of diabetes, smoking, hypertension, hyperlipidemia and increased arterial stiffness for the entire sample are summarized in Table 1. The demographic data stratified by the menopausal statuses of the women are presented in Table 2.

Table 1
Characteristics of the subjects in the sample.

Characteristics	Men	Women
N	761	901
Age, years	44.7±10.9	44.8±10.7
BMI, kg/m2	25.9±4.0	26.6±5.5
Waist circumference, cm	89.1±10.9	83.6±12.9
Fasting glucose, mg/dL	105.3±28.2	104.0±33.9
Smoking (%)	25.6	19.5
Hypertension (%)	47.6	38.1
Diabetes (%)	7.1	8.2
Hyperlipidemia (%)	26.9	25.9
Increased arterial stiffness (%)	19.3	12.1
PWV, m/s	7.9±2.3	7.4±2.1
TC, mg/dL	213.3±50.8	215.2±44.9
HDL-C, mg/dL	42.3±12.3	48.0±11.9
LDL-C, mg/dL	140.4±39.4	143.6±39.8
Non-HDL-C, mg/dL	171.6±55.2	167.5±47.6
VLDL-C, mg/dL	29.2±24.7	22.8±15.1
Triglycerides, mg/dL	163.5±175.9	118.4±85.8

• BMI, body mass index; PWV, pulse-wave velocity; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol.
• Hypertension: mean systolic blood pressure ≥140 mmHg, mean diastolic blood pressure ≥90 mmHg and/or anti-hypertensive drug use.
• Diabetes: fasting glucose ≥126 mg/dL and/or hypoglycemic drug use.
• Increased arterial stiffness: pulse-wave velocity (PWV) ≥10 m/s.
• Hyperlipidemia: TC≥240 mg/dL, LDL-C≥160 mg/dL, and/or hypolipidemic drug use.
• Continuous data are expressed as the mean±standard deviation.

Table 2
Clinical characteristics of the women stratified by menopause status.

Characteristics	Premenopausal Women	Postmenopausal Women	p-value
Age, y	40.2±8.9	54.8±6.7	<0.001
BMI, kg/m2	26.2±5.6	27.4±5.1	0.002
Waist circumference, cm	81.7±12.5	87.3±12.6	<0.001
Fasting glucose, mg/dL	99.4±22.5	114.1±49.6	<0.001
PWV, m/s	7.0±1.9	8.3±2.2	<0.001
CT, mg/dL	203.8±40.5	239.9±45.2	<0.001
LDL-C, mg/dL	135.2±36.6	161.6±41.2	<0.001
HDL-C, mg/dL	47.9±12.5	48.6±10.9	0.39
Non-HDL-C, mg/dL	156.5±42.5	191.2±50.3	<0.001
Triglycerides, mg/dL	106.6±78.1	145.0±96.9	<0.001
Smoking (%)	19.8	18.6	0.42
Increased arterial stiffness (%)	6.6	24.4	<0.001
Diabetes (%)	5.1	14.7	<0.001
Hypertension (%)	28.1	60.7	<0.001
Hyperlipidemia (%)	18.4	42.7	<0.001

• Continuous data are expressed as the mean±standard deviation.
• BMI, body mass index; PWV, pulse-wave velocity; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol.
• Hypertension: mean systolic blood pressure ≥140 mmHg, mean diastolic blood pressure ≥90 mmHg and/or anti-hypertensive drug use.
• Diabetes: fasting glucose ≥126 mg/dL and/or hypoglycemic drug use.
• Increased arterial stiffness: pulse wave velocity (PWV)≥10 m/s.
• Hyperlipidemia: TC≥240 mg/dL, LDL-C≥160 mg/dL, and/or hypolipidemic drug use.

Association Between Lipid Profile Parameters and Increased Arterial Stiffness

In men, only TC (OR=1.59; CI=1.02 to 2.48, p=0.04) was significantly associated with increased arterial stiffness (Table 3). However, in women, both HDL-C (OR=1.99; CI=1.18 to 3.35, p=0.01) and non-HDL-C (OR=1.61; CI=1.01 to 2.56, p=0.04) were known to be good predictors of the risk of increased arterial stiffness (Table 3). When stratified by menopausal status, the same analysis showed that this association was significant only for postmenopausal women (OR=2.06; CI=1.00 to 4.26, p=0.05 for HDL-C and OR=1.83; CI=1.01 to 3.33, p=0.04 for non-HDL-C) (Table 4). Accordingly, none of the lipid profile parameters were significantly associated with increased arterial stiffness in premenopausal women.

Table 3
Analysis of increased arterial stiffness according to the lipid profiles of the sample.

Variables	OR (95% CI), p-value
	Men	Women
TC (≥240 versus ≤239 mg/dL)	1.59 (1.02 to 2.48), 0.04	1.37 (0.86 to 2.18), 0.19
Triglycerides (≥200 versus ≤199 mg/dL)	1.54 (0.97 to 2.46), 0.07	1.67 (0.95 to 2.92), 0.07
HDL-C (≤39 versus ≥40 mg/dL)	0.98 (0.64 to 1.53), 0.94	1.99 (1.18 to 3.35), 0.01
LDL-C (≥160 versus ≤159 mg/dL)	1.10 (0.69 to 1.74), 0.70	1.15 (0.71 to 1.87), 0.56
Non-HDL-C (≥190 versus ≤189 mg/dL)	1.34 (0.87 to 2.06), 0.19	1.61 (1.01 to 2.56), 0.04

• TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; PWV, pulse wave velocity.
• Increased arterial stiffness = PWV≥10 m/s.
• All analyses were adjusted for mean blood pressure and age.
• p-values in boldface are significant.
• OR, odds ratio; 95%CI, 95% confidence interval.

Table 4
Analysis of increased arterial stiffness according to the lipid profiles of the women stratified by menopause status.

Variables	OR (95% CI), p-value
	Premenopausal Women	Postmenopausal Women
TC (≥ 240 versus ≤239 mg/dL)	1.28 (0.58 to 2.79), 0.54	1.37 (0.76 to 2.46), 0.30
Triglycerides (≥ 200 versus ≤199 mg/dL)	1.91 (0.76 to 4.80), 0.17	1.64 (0.81 to 3.31), 0.17
HDL-C (≤39 versus ≥40 mg/dL)	1.94 (0.89 to 4.23), 0.09	2.06 (1.00 to 4.26), 0.05
LDL-C (≥160 versus ≤159 mg/dL)	1.23 (0.56 to 2.69), 0.61	1.01 (0.55 to 1.87), 0.98
Non-HDL-C (≥190 versus ≤189 mg/dL)	1.13 (0.52 to 2.47), 0.35	1.83 (1.01 to 3.33), 0.04

• TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; PWV, pulse wave velocity.
• Increased arterial stiffness = PWV≥10 m/s.
• All analyses were adjusted for mean blood pressure and age.
• p-values in boldface are significant.
• OR, odds ratio; 95%CI, 95% confidence interval.

DISCUSSION

The main finding of our study was that there were positive associations between HDL-C and non-HDL-C and increased arterial stiffness in postmenopausal women. These results were not replicated in men and premenopausal women. In addition, postmenopausal women displayed higher LDL-C, triglyceride, TC, non-HDL-C and PWV levels than premenopausal women.

In the last few decades, researchers have noted an association between aging and dyslipidemia. In men, lipid profiles become more unfavorable because of the decreases in testosterone levels that occur with age. Similarly, in women, menopause is associated with a more atherogenic lipid profile than premenopausal status (²⁴). Studies have shown associations between the onset of menopause and the increased prevalence of cardiovascular risk factors. The lack of estrogen facilitates the development of diabetes, hypertension, obesity and dyslipidemia (²⁵). In our study, we also showed that a decrease in estrogen predisposes individuals to developing increased arterial stiffness, which is an additional and independent risk factor for CVD. Experimental studies have demonstrated that estrogen is highly effective in preventing LDL-C and VLDL-C oxidation (²⁶). In addition, endogenous estrogen production in premenopausal women is associated with low LDL-C levels and high HDL-C levels (²⁷). Mogarekar and Kulkarni (²⁸) showed that postmenopausal women had significantly increased serum triglycerides and small dense LDL-C levels, as well as significantly decreased HDL-C and paraoxonase-1 levels, compared to premenopausal women. These findings may explain the low prevalence of CVD in premenopausal women. In the present study, postmenopausal women displayed worse lipid profiles and higher prevalences of hypertension, diabetes and increased arterial stiffness than premenopausal women. Thus, it is possible that the development of cardiometabolic disorders can be partially explained by deficient or absent estrogen production.

Increased central arterial stiffness is an important determinant of CVD risk (¹), and previous studies have demonstrated that an association exists between hypercholesterolemia and stiffer blood vessels (⁹). In our study, the lipid profile was associated with increased arterial stiffness in postmenopausal women; i.e., high HDL-C and non-HDL-C levels were associated with increased arterial stiffness. As previously described, estrogen plays a key role in lipid metabolism and cardiovascular risk among women (²⁵,²⁷). Thus, our data suggest that increased arterial stiffness in postmenopausal women may result from the lipid profile parameter worsening associated with decreased estrogen levels.

Several studies have focused on the relationship between the lipid profile and arterial stiffness. Holewijn et al. (¹¹) studied 1517 individuals aged 50-70 years and showed that non-HDL-C was superior to LDL-C with respect to identifying individuals with compromised cardiovascular phenotypes, including individuals with high arterial stiffness, from the general population, results that partially corroborated ours. In contrast, Zhao et al. (¹³) studied a middle-aged and elderly Chinese population and showed that the non-HDL-c/HDL-C ratio was superior to traditional lipid variables with respect to estimating arterial stiffness risk. Finally, Wang et al. (¹²) studied 2375 individuals aged 40-96 years and showed that only LDL-C and HDL-C were independently associated with aortic stiffness. However, that study did not evaluate the role of non-HDL-C with respect to the risk of aortic stiffness. As stated above, we were limited with respect to our ability to compare our results with those of previous studies in the literature due to the variety of methods used to assess arterial stiffness in those studies and the differences between those studies and ours with regard to the statistical methods used for analyses.

In the present study, non-HDL-C was a good predictor of the risk of increased arterial stiffness in postmenopausal women belonging to an urban Brazilian population. Our data were partially corroborated by the results of several population studies demonstrating that non-HDL-C is a better marker of CVD risk than LDL-C alone (²⁹,³⁰). Another important finding of our study is that the association between the lipid profile and increased arterial stiffness was significant only in postmenopausal women, a finding suggestive of the impact of estrogen on lipid metabolism (²⁶,²⁷).

Our study had some limitations. First, we did not obtain measurements of follicle stimulating hormone (FSH) levels; therefore, we were unable to make a laboratory diagnosis of menopause. Second, this study was a cross-sectional analysis. Therefore, a causal relationship between increased arterial stiffness and poor lipid profiles could not be established. Third, in our study, some women were treated with postmenopausal hormone replacement therapy. Fourth, hypolipidemic therapy can decrease arterial stiffness (³¹), and some participants enrolled in the our study use lipid-lowering drugs, which may have slightly influenced our findings.

In summary, this study showed that non-HDL-C may be a good predictor of the risk of increased arterial stiffness in postmenopausal women. Thus, we surmise that non-HDL-C may a useful tool for the assessing the risk of arterial stiffness during the postmenopausal period.

REFERENCES

• ¹
  Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor?Am J Epidemiol. 1994;140(8):669-82, http://dx.doi.org/10.1093/oxfordjournals.aje.a117315
  » http://dx.doi.org/10.1093/oxfordjournals.aje.a117315
• ²
  Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study.Circulation. 2006;113(5):657-63, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.555235
  » http://dx.doi.org/10.1161/CIRCULATIONAHA.105.555235
• ³
  Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 55(13):1318-27.
• ⁴
  Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol. 2007;34(7):647-51.
• ⁵
  Vaitkevicius PV, Fleg JL, Engel JH, O'Connor FC, Wright JG, Lakatta LE, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation. 1993;88(4 Pt 1):1456-62, http://dx.doi.org/10.1161/01.CIR.88.4.1456
  » http://dx.doi.org/10.1161/01.CIR.88.4.1456
• ⁶
  Stewart AD, Jiang B, Millasseau SC, Ritter JM, Chowienczyk PJ. Acute reduction of blood pressure by nitroglycerin does not normalize large artery stiffness in essential hypertension.Hypertension. 2006;48(3):404-10, http://dx.doi.org/10.1161/01.HYP.0000237669.64066.c5
  » http://dx.doi.org/10.1161/01.HYP.0000237669.64066.c5
• ⁷
  Whincup PH, Gilg JA, Donald AE, Katterhorn M, Oliver C, Cook DG, et al. Arterial distensibility in adolescents: the influence of adiposity, the metabolic syndrome, and classic risk factors.Circulation. 2005;112(12):1789-97, http://dx.doi.org/10.1161/CIRCULATIONAHA.104.532663
  » http://dx.doi.org/10.1161/CIRCULATIONAHA.104.532663
• ⁸
  Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.Circulation. 2001;103(7):987-92, http://dx.doi.org/10.1161/01.CIR.103.7.987
  » http://dx.doi.org/10.1161/01.CIR.103.7.987
• ⁹
  Wilkinson I, Cockcroft JR. Cholesterol, lipids and arterial stiffness. Adv Cardiol. 2007;44:261-77, http://dx.doi.org/10.1159/000096747
  » http://dx.doi.org/10.1159/000096747
• ¹⁰
  Zaydun G, Tomiyama H, Hashimoto H, Arai T, Koji Y, Yambe M, et al. Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase.Atherosclerosis. 2006;184(1):137-42, http://dx.doi.org/10.1016/j.atherosclerosis.2005.03.043
  » http://dx.doi.org/10.1016/j.atherosclerosis.2005.03.043
• ¹¹
  Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med. 2010;268(6):567-77, http://dx.doi.org/10.1111/j.1365-2796.2010.02277.x
  » http://dx.doi.org/10.1111/j.1365-2796.2010.02277.x
• ¹²
  Wang F, Ye P, Luo L, Xiao W, Qi L, Bian S, et al. Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Invest. 2011;41(9):929-36, http://dx.doi.org/10.1111/j.1365-2362.2011.02481.x
  » http://dx.doi.org/10.1111/j.1365-2362.2011.02481.x
• ¹³
  Zhao W, Gong W, Wu N, Li Y, Ye K, Lu B, et al. Association of lipid profiles and the ratios with arterial stiffness in middle-aged and elderly Chinese. Lipids Health Dis.2014;13:37, http://dx.doi.org/10.1186/1476-511X-13-37
  » http://dx.doi.org/10.1186/1476-511X-13-37
• ¹⁴
  Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review.Hypertension. 2009;54(6):1328-36, http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.137653
  » http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.137653
• ¹⁵
  Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.Circulation. 1994;90(1):583-612.
• ¹⁶
  The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41(2):105-14, http://dx.doi.org/10.1016/0895-4356(88)90084-4
  » http://dx.doi.org/10.1016/0895-4356(88)90084-4
• ¹⁷
  Rodrigues SL, Baldo MP, Mill JG. Association of waist-stature ratio with hypertension and metabolic syndrome: population-based study. Arq Bras Cardiol. 2010;95(2):186-91, http://dx.doi.org/10.1590/S0066-782X2010005000073
  » http://dx.doi.org/10.1590/S0066-782X2010005000073
• ¹⁸
  Pereira AC, Sposito AC, Mota GF, Cunha RS, Herkenhoff FL, Mill JG, et al. Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: new evidence for a direct effect of lipids in arterial blood pressure.Atherosclerosis. 2006;184(1):193-200, http://dx.doi.org/10.1016/j.atherosclerosis.2005.03.035
  » http://dx.doi.org/10.1016/j.atherosclerosis.2005.03.035
• ¹⁹
  Xavier HT, Izar MC, Faria Neto JR, Assad MH, Rocha VZ, Sposito AC, et al. [V Brazilian Guidelines on Dyslipidemias and Prevention of Atherosclerosis]. Arq Bras Cardiol. 2013;101(4 Suppl 1):1-20, http://dx.doi.org/10.5935/abc.2013S010
  » http://dx.doi.org/10.5935/abc.2013S010
• ²⁰
  Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser.1985;727:1-113.
• ²¹
  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).JAMA. 2001;285(19):2486-97.
• ²²
  Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445-8, http://dx.doi.org/10.1097/HJH.0b013e32834fa8b0
  » http://dx.doi.org/10.1097/HJH.0b013e32834fa8b0
• ²³
  Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies.Hypertension. 1995;26(3):485-90, http://dx.doi.org/10.1161/01.HYP.26.3.485
  » http://dx.doi.org/10.1161/01.HYP.26.3.485
• ²⁴
  Lombardi M, Mercuro G, Fini M, Rosano GM. Gender-specific aspects of treatment of cardiovascular risk factors in primary and secondary prevention. Fundam Clin Pharmacol. 2010;24(6):699-705, http://dx.doi.org/10.1111/j.1472-8206.2010.00834.x
  » http://dx.doi.org/10.1111/j.1472-8206.2010.00834.x
• ²⁵
  Barton M, Meyer MR, Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?Arterioscler Thromb Vasc Biol. 2007;27(8):1669-72, http://dx.doi.org/10.1161/ATVBAHA.106.130260
  » http://dx.doi.org/10.1161/ATVBAHA.106.130260
• ²⁶
  Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett. 1987;210(1):37-9, http://dx.doi.org/10.1016/0014-5793(87)81293-0
  » http://dx.doi.org/10.1016/0014-5793(87)81293-0
• ²⁷
  Knopp RH, Paramsothy P, Retzlaff BM, Fish B, Walden C, Dowdy A, et al. Sex differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Cardiol Rep. 2006;8(6):452-9, http://dx.doi.org/10.1007/s11886-006-0104-0
  » http://dx.doi.org/10.1007/s11886-006-0104-0
• ²⁸
  Mogarekar MR, Kulkarni SK. Small Dense Low Density Lipoprotein Cholesterol, Paraoxonase 1 and Lipid Profile in Postmenopausal Women: Quality or Quantity?Arch Med Res. 2015;46(7):534-8, http://dx.doi.org/10.1016/j.arcmed.2015.08.007
  » http://dx.doi.org/10.1016/j.arcmed.2015.08.007
• ²⁹
  Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.JAMA. 2005;294(3):326-33, http://dx.doi.org/10.1001/jama.294.3.326
  » http://dx.doi.org/10.1001/jama.294.3.326
• ³⁰
  Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease.JAMA. 2009;302(18):1993-2000, http://dx.doi.org/10.1001/jama.2009.1619
  » http://dx.doi.org/10.1001/jama.2009.1619
• ³¹
  Kanaki AI, Sarafidis PA, Georgianos PI, Kanavos K, Tziolas IM, Zebekakis PE, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013;26(5):608-16, http://dx.doi.org/10.1093/ajh/hps098
  » http://dx.doi.org/10.1093/ajh/hps098

Publication Dates

• Publication in this collection
  Feb 2017

History

• Received
  9 Aug 2016
• Reviewed
  7 Oct 2016
• Accepted
  24 Nov 2016